DermaXon announces its partnership with VantAI, a Roivant Biosciences Vant company, for the rapid acceleration of two of its drug development programs. VantAI leads the computational drug discovery space with technology at the bleeding edge of machine learning and...read more
September 2019: DermaXon received a Phase 1 STTR Grant funding from the National Institute of Neurological Disorders and Stroke to support preclinical efficacy studies for a novel drug treatment for pruritus. This award, titled “TOPICAL SELECTIVE T-TYPE BLOCKERS FOR...read more
DermaXon LLC awarded grant for continued development of DX308 drug candidate for the treatment of Ichthyosis
MiSSOULA, Montana, Nov. 20, 2018 – DermaXon was been awarded a research grant from The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to further research treatment options for Ichthyosis.read more
June 2018: DermaXon received a Phase 1 STTR Grant funding from the National Institute of Neurological Disorders and Stroke to support preclinical efficacy studies for a novel drug treatment for pain. This award titled “Topical selective T-type blockers for the...read more
June, 2020: BIO DigitalDermaXon has been selected by the NIH to present its pipeline at BIO digital, Innovation Zone. This virtual gathering of the global biotech industry provides access to key partners via BIO One-on-One Partnering. The Innovation Zone is a...read more
In the past, we have presented or had posters at conferences all across the country. Learn more about the events we attended.read more
Characterization of CYP26B1-selective Inhibitor, DX314, as a Potential Therapeutic for Keratinization Disorders.
Abstract: Inhibition of cytochrome P450 (CYP)-mediated retinoic acid (RA) metabolism by RA metabolism blocking agents (RAMBAs) increases endogenous retinoids and is an alternative to retinoid therapy. Currently available RAMBAs (i.e. liarozole and talarozole) tend to...